Effect of genetic polymorphisms on Alzheimer’s disease treatment outcomes: an update

References

• MannDMPyramidal nerve cell loss in Alzheimer’s diseaseNeurodegeneration1996544234279117557
   PubMedGoogle Scholar
• NoorAZahidSA review of the role of synaptosomal-associated protein 25 (SNAP-25) in neurological disordersInt J Neurosci2017127980581127734716
   PubMed Web of Science ®Google Scholar
• GueriniFRFarinaECostaASAPOE and SNAP-25 polymorphisms predict the outcome of multidimensional stimulation therapy rehabilitation in Alzheimer’s diseaseNeurorehabil Neural Repair201630988389327075583
   PubMed Web of Science ®Google Scholar
• ShengMSabatiniBLSüdhofTCSynapses and Alzheimer’s diseaseCold Spring Harb Perspect Biol201245a00577722491782
   PubMed Web of Science ®Google Scholar
• HaroldDMacgregorSPattersonCEA single nucleotide polymorphism in ChAT influences response to acetylcholinesterase inhibitors in Alzheimer’s diseasePharmacogenet Genomics2006162757716424819
   PubMed Web of Science ®Google Scholar
• MinocherhomjiSTollefsbolTOSinghKKMitochondrial regulation of epigenetics and its role in human diseasesEpigenetics20127432633422419065
   PubMed Web of Science ®Google Scholar
• JiangQJinSJiangYAlzheimer’s disease variants with the genome-wide significance are significantly enriched in immune pathways and active in immune cellsMol Neurobiol201754159460026746668
   PubMed Web of Science ®Google Scholar
• WengPHChenJHChenTFCHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer’s diseasePLoS One2013812e8405924391883
   PubMed Web of Science ®Google Scholar
• ClarelliFMasciaESantangeloRCHRNA7 gene and response to cholinesterase inhibitors in an Italian cohort of Alzheimer’s disease patientsJ Alzheimers Dis20165241203120827104904
   PubMed Web of Science ®Google Scholar
• BragaILSSilvaPNFuruyaTKEffect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer’s diseaseAm J Alzheimers Dis Other Demen201530213914424951635
   PubMed Web of Science ®Google Scholar
• YoonHMyungWLimSWAssociation of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer’s diseasePharmacopsychiatry201548311111725730470
   PubMed Web of Science ®Google Scholar
• LeeKULeeJHLeeDYThe effect of choline acetyltransferase genotype on donepezil treatment response in patients with Alzheimer’s diseaseClin Psychopharmacol Neurosci201513216817326243844
   PubMed Web of Science ®Google Scholar
• ScacchiRGambinaGMorettoGCorboRMVariability of AChE, BCHE, and ChAT genes in the late-onset form of Alzheimer’s disease and relationships with response to treatment with donepezil and rivastig-mineAm J Med Genet B Neuropsychiatr Genet2009150B450250718780301
   PubMed Web of Science ®Google Scholar
• LiuMZhangYHuoYRInfluence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer’s disease in ChinaDement Geriatr Cogn Dis Extra20144345045625538729
   PubMedGoogle Scholar
• Klimkowicz-MrowiecAWolkowPSadoMInfluence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with Alzheimer’s diseaseNeuropsychiatr Dis Treat201391029103323950644
   PubMed Web of Science ®Google Scholar
• PilottoAFranceschiMD’OnofrioGEffect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer diseaseNeurology2009731076176719738170
   PubMed Web of Science ®Google Scholar
• LuJWanLZhongYStereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer’s diseaseJ Pharmacol Sci2015129318819526603528
   PubMed Web of Science ®Google Scholar
• SonaliNTripathiMSagarRVelpandianTSubbiahVImpact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinester-ase inhibitors and memantine treatment in mild to moderate Alzheimer’s diseaseDement Geriatr Cogn Disord2014371–2587024107805
   PubMed Web of Science ®Google Scholar
• ZhongYZhengXMiaoYWanLYanHWangBEffect of cyp2d6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s diseaseAm J Med Sci2013345322222622986607
   PubMed Web of Science ®Google Scholar
• AlbaniDMartinelli BoneschiFBiellaGReplication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patientsJ Alzheimers Dis201230474574922465999
   PubMed Web of Science ®Google Scholar
• SeripaDBizzarroAPilottoARole of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s diseasePharmacogenet Genomics201121422523020859244
   PubMed Web of Science ®Google Scholar
• SonaliNTripathiMSagarRVelpandianTSubbiahVClinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer’s patientsCNS Neurosci Ther2013192919723206182
   PubMed Web of Science ®Google Scholar
• VarsaldiFMiglioGScordoMGImpact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patientsEur J Clin Pharmacol200662972172616845507
   PubMed Web of Science ®Google Scholar
• PolaRFlexACiaburriMResponsiveness to cholinesterase inhibitors in Alzheimer’s disease: a possible role for the 192 Q/R polymorphism of the PON-1 geneNeurosci Lett2005382333834115925115
   PubMed Web of Science ®Google Scholar
• LuJFuJZhongYAssociation between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer’s diseaseBrain Res Bull20181401429605487
   PubMed Web of Science ®Google Scholar
• LuJFuJZhongYThe roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer’s diseaseNeuroscience Letters2016614434826768225
   PubMed Web of Science ®Google Scholar
• MirandaLFJRGomesKBTitoPALClinical response to donepezil in mild and moderate dementia: relationship to drug plasma concentration and CYP2D6 and APOE genetic polymorphismsJ Alzheimers Dis201755253954927716659
   PubMed Web of Science ®Google Scholar
• BlesaRAguilarMCasanovaJPRelationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer diseaseAlzheimer Dis Assoc Disord200620424825417132969
   PubMed Web of Science ®Google Scholar
• ScacchiRGambinaGBroggioECorboRMSex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer’s diseaseInt J Geriatr Psychiatry201429661061524150894
   PubMed Web of Science ®Google Scholar
• FitzNFCarterAYTapiasVABCA1 deficiency affects basal cognitive deficits and dendritic density in miceJ Alzheimers Dis20175631075108528106559
   PubMed Web of Science ®Google Scholar
• LuptonMKProitsiPLinKThe role of ABCA1 gene sequence variants on risk of Alzheimer’s diseaseJ Alzheimers Dis201438489790624081377
   PubMed Web of Science ®Google Scholar
• PoirierJDelisleMCQuirionRApolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer diseaseProc Natl Acad Sci1995922612260122648618881
   PubMed Web of Science ®Google Scholar
• GetzGSReardonCAParaoxonase, a cardioprotective enzyme: continuing issuesCurr Opin Lipidol200415326126715166781
   PubMed Web of Science ®Google Scholar
• AdkinsSGanKNModyMLa DuBNMolecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymesAm J Hum Genet19935235986087916578
   PubMed Web of Science ®Google Scholar
• HumbertRAdlerDADistecheCMHassettCOmiecinskiCJFurlongCEThe molecular basis of the human serum paraoxonase activity polymorphismNat Genet19933173768098250
   PubMed Web of Science ®Google Scholar
• CoyleJTPriceDLDelongMRAlzheimer’s disease: a disorder of cortical cholinergic innervationScience19832194589118411906338589
   PubMed Web of Science ®Google Scholar
• LondonEDBallMJWallerSBNicotinic binding sites in cerebral cortex and hippocampus in Alzheimer’s dementiaNeurochem Res19891487457502812250
   PubMed Web of Science ®Google Scholar
• FrazierCJBuhlerAVWeinerJLDunwiddieTVSynaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneuronsJ Neurosci19981820822882359763468
   PubMed Web of Science ®Google Scholar
• Takada-TakatoriYKumeTSugimotoMKatsukiHSugimotoHAkaikeAAcetylcholinesterase inhibitors used in treatment of Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascadeNeuropharmacology200651347448616762377
   PubMed Web of Science ®Google Scholar
• AkaikeATakada-TakatoriYKumeTIzumiYMechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotectionJ Mol Neurosci2010401–221121619714494
   PubMed Web of Science ®Google Scholar
• WonnacottSBarikJDickinsonJJonesIWNicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmittersJ Mol Neurosci2006301–213714017192660
   PubMed Web of Science ®Google Scholar
• KumeTSugimotoMTakadaYUp-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neuronsEur J Pharmacol20055271–3778516313899
   PubMed Web of Science ®Google Scholar
• EllisJMCholinesterase inhibitors in the treatment of dementiaJ Am Osteopath Assoc2005105314515815863734
   PubMedGoogle Scholar
• JannMWShirleyKLSmallGWClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitorsClin Pharmacokinet2002411071973912162759
   PubMed Web of Science ®Google Scholar
• WilcockGKEsiriMMBowenDMSmithCCCorrelation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalitiesJ Neurol Sci1982572–34074177161627
   PubMed Web of Science ®Google Scholar
• KozakMRecognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6Embo J1997169248224929171361
   PubMed Web of Science ®Google Scholar
• ÖsterlundMKHurdYLEstrogen receptors in the human forebrain and the relation to neuropsychiatric disordersProg Neurobiol200164325126711240308
   PubMed Web of Science ®Google Scholar
• AbrahamBKAdithanCGenetic polymorphism of CYP2D6Indian J Pharmacol2001333147169
   Google Scholar
• National Institute of HealthProgress Report on Alzheimer’s Disease 2004–2005: New Discoveries, New InsightsMarylandNational Institute of Health2005
   Google Scholar
• GoldbergACurtisCLKleimJALinking genes to neurological clinical practice: the genomic basis for neurorehabilitationJNPT2015391526125415554
   PubMed Web of Science ®Google Scholar
• LiuCCLiuCCKanekiyoTXuHBuGApolipoprotein E and Alzheimer disease: risk, mechanisms and therapyNat Rev Neurol20139210611823296339
   PubMed Web of Science ®Google Scholar
• ChangJYHStamerWDBertrandJRole of nitric oxide in murine conventional outflow physiologyAm J Physiol Cell Physiol20153094C205C21426040898
   PubMed Web of Science ®Google Scholar
• BrungerATStructural insights into the molecular mechanism of Ca(2+)-dependent exocytosisCurr Opin Neurobiol200010329330210851178
   PubMed Web of Science ®Google Scholar
• PozziDCondliffeSBozziYActivity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channelsProc Natl Acad Sci2008105132332818162553
   PubMed Web of Science ®Google Scholar
• BaglioFGriffantiLSaibeneFLMultistimulation group therapy in Alzheimer’s disease promotes changes in brain functioningNeurorehabilitation and Neural Repair2015291132424788581
   PubMed Web of Science ®Google Scholar
• BraidaDGueriniFRPonzoniLAssociation between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategiesTransl Psychiatry201551e50025629685
   PubMed Web of Science ®Google Scholar
• AntonucciFCorradiniIFossatiGTomasoniRMennaEMatteoliMSNAP-25, a known presynaptic protein with emerging postsynaptic functionsFrontiers Synapt Neurosci20168897
   Google Scholar
• McKeeAGLoscherJSO’SullivanNCAAV-mediated chronic over-expression of SNAP-25 in adult rat dorsal hippocampus impairs memory-associated synaptic plasticityJ Neurochem20101124991100420002519
   PubMed Web of Science ®Google Scholar
• Owe-LarssonBBerglundMKristenssonKPerturbation of the synaptic release machinery in hippocampal neurons by overexpression of SNAP-25 with the Semliki Forest virus vectorEur J Neurosci19991161981198710336667
   PubMed Web of Science ®Google Scholar
• Wernette-HammondMELauerSJCorsiniAWalkerDTaylorJMRallSCGlycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194J Biol Chem198926415909491012498325
   PubMed Web of Science ®Google Scholar
• XuQBernardoAWalkerDKanegawaTMahleyRWHuangYProfile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the APOE locusJ Neurosci200626194985499416687490
   PubMed Web of Science ®Google Scholar
• PitasREBoylesJKLeeSHHuiDWeisgraberKHLipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipo-protein B,E(LDL) receptors in the brainJ Biol Chem19872622914352143603115992
   PubMed Web of Science ®Google Scholar
• GrehanSTseETaylorJMTwo distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brainJ Neurosci200121381282211157067
   PubMed Web of Science ®Google Scholar
• MahleyRWWeisgraberKHHuangYApolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s diseaseProc Natl Acad Sci2006103155644565116567625
   PubMed Web of Science ®Google Scholar
• MaJBrewerHBPotterHAlzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by a beta-related peptidesNeurobiol Aging19961757737808892351
   PubMed Web of Science ®Google Scholar
• CastanoEMPrelliFWisniewskiTFibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein EBiochem J1995306Pt 25996047534068
   PubMed Web of Science ®Google Scholar
• KimJBasakJMHoltzmanDMThe role of apolipoprotein E in Alzheimer’s diseaseNeuron200963328730319679070
   PubMed Web of Science ®Google Scholar
• PolitoLAbbondanzaSVaccaroRCognitive stimulation in cognitively impaired individuals and cognitively healthy individuals with a family history of dementia: short-term results from the “Allena-Mente” randomized controlled trialInt J Geriatr Psychiatry201530663163825187003
   PubMed Web of Science ®Google Scholar
• MauchDHNäglerKSchumacherSCNS synaptogenesis promoted by glia-derived cholesterolScience200129455451354135711701931
   PubMed Web of Science ®Google Scholar
• WhiteFNicollJARosesADHorsburghKImpaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesionNeurobiol Dis20018461162511493026
   PubMed Web of Science ®Google Scholar
• TeterBXuPTGilbertJRRosesADGalaskoDColeGMDefective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative functionJ Neurosci Res200268333133612111863
   PubMed Web of Science ®Google Scholar
• TangMRaoDMaCEvaluation of choline acetyltransferase gene polymorphism (2384 G/A) in Alzheimer’s disease and mild cognitive impairmentDement Geriatr Cogn Disord200826191418562794
   PubMed Web of Science ®Google Scholar
• GrünblattEZehetmayerSBartlJGenetic risk factors and markers for Alzheimer’s disease and/or depression in the vita studyJ Psychiatr Res200943329830818603262
   PubMed Web of Science ®Google Scholar
• Mengel-FromJChristensenKThinggaardMMcGueMChristiansenLGenetic variants in the choline acetyltransferase (ChAT) gene are modestly associated with normal cognitive function in the elderlyGenes Brain Behav201110887688221883924
   PubMed Web of Science ®Google Scholar
• LeeJJJoSAParkJHCholine acetyltransferase 2384G>a polymorphism and the risk of Alzheimer diseaseAlzheimer Dis Assoc Disord2012261818721602657
   PubMed Web of Science ®Google Scholar
• YangXLiuWYiMCholine acetyltransferase may contribute to the risk of Tourette syndrome: combination of family-based analysis and case-control studyWorld J Biol Psychiatry201716
   Web of Science ®Google Scholar
• WengPHChenJHChenTFCHRNA7 polymorphisms and dementia risk: interactions with apolipoprotein ε4 and cigarette smokingSci Rep2016612723127249957
   PubMed Web of Science ®Google Scholar
• AmstutzUHenricksLMOfferSMClinical pharmacogenetics implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 updateClin Pharmacol Ther2018103221021629152729
   PubMed Web of Science ®Google Scholar
• GoetzMPSangkuhlKGuchelaarHJClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyClin Pharmacol Ther2018103577077729385237
   PubMed Web of Science ®Google Scholar
• JohnsonJACaudleKEGongLClinical pharmacogenetics implementation Consortium (CPIC) guideline for Pharmacogenetics-Guided warfarin dosing: 2017 updateClin Pharmacol Ther2017102339740428198005
   PubMed Web of Science ®Google Scholar
• BellGCCaudleKEWhirl-CarrilloMClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetronClin Pharmacol Ther2017102221321828002639
   PubMed Web of Science ®Google Scholar
• HicksJKSangkuhlKSwenJJClinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateClin Pharmacol Ther20171021374427997040
   PubMed Web of Science ®Google Scholar